Magnetic resonance imaging of acute myocardial ischemia using a manganese chelate, Mn-DPDP

O H Pomeroy1, M Wendland, S Wagner

  • 1Department of Radiology, University of California, San Francisco.

Insights

This study shows that manganese chelate of N, N'-Bis (pyridoxal-5-phosphate) ethylenediamine-N, N'-diacetic acid (Mn-DPDP) can effectively delineate acute myocardial ischemia in rats. The contrast agent distinguished between normal and ischemic heart tissue for up to an hour post-injection without adverse hemodynamic effects.

Area of Science:

  • Cardiovascular Imaging
  • Medical Contrast Agents
  • Myocardial Ischemia Research

Background:

  • Acute myocardial ischemia poses a significant diagnostic challenge.
  • Effective delineation of ischemic areas is crucial for timely intervention.
  • Novel contrast agents are needed to improve diagnostic accuracy in cardiac imaging.

Purpose of the Study:

  • To evaluate the efficacy of manganese chelate of N, N '-Bis (pyridoxal-5-phosphate) ethylenediamine-N, N '-diacetic acid (Mn-DPDP) in delineating acute myocardial ischemia.
  • To assess the safety and hemodynamic effects of Mn-DPDP in a rat model.
  • To determine the duration of contrast enhancement and visual discrimination between normal and ischemic myocardium.

Main Methods:

  • Nine adult rats underwent left coronary artery (LCA) occlusion.
  • Gated transaxial cardiac MRI was performed at a 2 Tesla magnet.
  • Mn-DPDP was administered intravenously, with imaging before and at intervals after injection.

Main Results:

  • Mn-DPDP significantly increased signal intensity in normal myocardium.
  • Ischemic myocardium showed a markedly lower signal intensity increase compared to normal tissue.
  • Visual discrimination between normal and ischemic myocardium was maintained for at least one hour post-injection.
  • No adverse hemodynamic effects were observed in isolated rat hearts.

Conclusions:

  • Mn-DPDP demonstrates significant potential for delineating the area at risk (jeopardy area) following coronary occlusion.
  • The agent provides sustained contrast enhancement, enabling visualization of ischemic myocardium for up to one hour.
  • Mn-DPDP is a safe contrast agent with no observed hemodynamic compromise in the tested model.